OneroRx adds lower-cost diabetes drug Brenzavvy to select pharmacies

By AI, Created 2:16 PM UTC, June 01, 2026, /AGP/ – OneroRx said June 1, 2026, that Brenzavvy, a lower-cost type 2 diabetes medication, is now available at select pharmacies in several states. The launch is aimed at improving affordability and access for patients who need blood sugar control.

Why it matters: - Brenzavvy gives adults with type 2 diabetes another lower-cost SGLT2 inhibitor option. - The launch targets a common barrier to care: medication affordability. - Better affordability can support prescription adherence and long-term diabetes management.

What happened: - OneroRx announced the immediate availability of Brenzavvy, also known as bexagliflozin. - The medication is now offered at select OneroRx pharmacies in Iowa, Missouri, Illinois and Indiana. - The announcement was made June 1, 2026, from West Des Moines, Iowa. - Brenzavvy was approved by the FDA in 2023 and was developed by TheracosBio.

The details: - Brenzavvy is intended to help improve blood glucose control in adults with type 2 diabetes. - OneroRx described Brenzavvy as one of the most cost-effective options in its class. - Select participating pharmacies include Medicap Pharmacy in Urbandale, Iowa; Sinks Pharmacy in Rolla, Missouri; Lee’s Summit Pharmacy in Lee’s Summit, Missouri; Local Health Pharmacy in Chicago; Juniper Pharmacy in St. Louis; and Willowbrook Pharmacy in Carmel, Indiana. - For a limited time, patients can receive $38 off a three-month supply. - Patients should consult a pharmacist or healthcare provider to determine eligibility. - OneroRx said the launch fits alongside its CGM offerings as part of a broader affordability push. - OneroRx said it provides affordable, high-quality pharmacy services to underserved communities and fills more than 5 million prescriptions annually across 92 locations in eight states. - TheracosBio said it develops affordable therapeutics for diseases with significant societal impact.

Between the lines: - The launch positions OneroRx around price-sensitive chronic care, where out-of-pocket costs can shape whether patients stay on treatment. - Partnering with TheracosBio lets OneroRx broaden its diabetes portfolio without developing a drug itself. - The promotion and selective rollout suggest a measured distribution strategy rather than a national launch.

What’s next: - OneroRx said patients can visit the company’s patient page to find a participating pharmacy. - More pharmacy partnerships could expand access if demand for the lower-cost option grows. - OneroRx said it will keep expanding offerings aimed at improving access to care.